Kwality Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Kwality Pharmaceuticals is Ramesh Arora, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. bezit rechtstreeks 26.9% van de aandelen van het bedrijf, ter waarde ₹ 2.48B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 8.9 jaar.

Belangrijke informatie

Ramesh Arora

Algemeen directeur

₹6.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.8yrs
Eigendom CEO	26.9%
Management gemiddelde ambtstermijn	8.8yrs
Gemiddelde ambtstermijn bestuur	8.9yrs

Recente managementupdates

Recent updates

CEO

Ramesh Arora (70 yo)

8.8yrs

Tenure

₹6,000,000

Compensatie

Mr. Ramesh Arora has been the Managing Director and Executive Director of Kwality Pharmaceuticals Limited since January 16, 2016 and May 4, 1983 respectively. Mr. Arora has more than 3 decades of experienc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ramesh Arora	MD & Director	8.8yrs	₹6.00m	26.9% ₹ 2.5b
Aditya Arora	CFO & Whole Time Director	8.8yrs	₹4.20m	11.95% ₹ 1.1b
Ajay Arora	Whole Time Director	no data	₹6.00m	13.59% ₹ 1.3b
Anju Arora	Whole Time Director	no data	₹2.40m	1.31% ₹ 120.7m
Geeta Arora	Whole Time Director	no data	₹2.40m	1.07% ₹ 99.2m
Gurpreet Kaur	Company Secretary & Compliance Officer	5.3yrs	geen gegevens	geen gegevens
Shankar Dayal	Chief Domestic Sales Officer	no data	geen gegevens	geen gegevens

8.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 539997 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ramesh Arora	MD & Director	41.5yrs	₹6.00m	26.9% ₹ 2.5b
Aditya Arora	CFO & Whole Time Director	9.1yrs	₹4.20m	11.95% ₹ 1.1b
Ajay Arora	Whole Time Director	29.3yrs	₹6.00m	13.59% ₹ 1.3b
Anju Arora	Whole Time Director	14.1yrs	₹2.40m	1.31% ₹ 120.7m
Geeta Arora	Whole Time Director	14.1yrs	₹2.40m	1.07% ₹ 99.2m
Kiran Verma	Non-Executive Independent Director	8.8yrs	₹180.00k	geen gegevens
Pankaj Takkar	Non-Executive Independent Director	8.8yrs	₹108.00k	0.029% ₹ 2.7m
Ravi Singh	Non-Executive Independent Director	8.8yrs	₹20.00k	geen gegevens
Kartik Kapur	Independent Director	3.8yrs	₹20.00k	geen gegevens
Prashanth Vellanki	Non-Executive & Independent Director	1.7yrs	₹7.00k	geen gegevens

8.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 539997 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.9 jaar).

Kwality Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 24, 2024

Insufficient new directors

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Less than half of directors are independent

Recent updates

Second quarter 2025 earnings released: EPS: ₹8.15 (vs ₹5.99 in 2Q 2024)

Investor sentiment improves as stock rises 19%

Kwality Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 30, 2024

New minor risk - Share price stability

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 24, 2024

Investor sentiment improves as stock rises 28%

First quarter 2025 earnings released: EPS: ₹8.04 (vs ₹5.10 in 1Q 2024)

Kwality Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 10, 2024

Full year 2024 earnings released: EPS: ₹22.76 (vs ₹18.67 in FY 2023)

Kwality Pharmaceuticals Limited to Report Q4, 2024 Results on May 23, 2024

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: ₹7.39 (vs ₹6.82 in 3Q 2023)

Insufficient new directors

Kwality Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Kwality Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 04, 2023

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹5.10 (vs ₹9.99 in 1Q 2023)

Kwality Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹18.16 (vs ₹116 in FY 2022)

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ₹6.82 (vs ₹15.20 in 3Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Second quarter 2023 earnings released: EPS: ₹8.82 (vs ₹57.33 in 2Q 2022)

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 30, 2023

Investor sentiment improved over the past week

First quarter 2023 earnings released

Kwality Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 28, 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

CFO & Whole Time Director recently bought ₹1.3m worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2022 earnings released: EPS ₹90.57 (vs ₹6.70 in 1H 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹14.60 (vs ₹8.02 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: ₹61.15

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹49.00

Kwality Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 13, 2020

Kwality Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2020

Kwality Pharmaceuticals Limited to Report Second Half, 2020 Results on Jul 13, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd